Project Grant R56AG087357
Award Date
9/30/24
Completion Date
8/31/25
Dollars Obligated
$885K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This Federal Project Grant award of $154,748 from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop an ultrasensitive blood-based diagnostic tool for Alzheimer's disease (AD). The grant recipient, Brigham & Women's Hospital Inc., will work closely with Dr. David Walt at the Wyss Institute to create a pipeline for efficiently isolating extracellular vesicles (EVs) from plasma and quantitatively assessing the phosphorylation state of AD biomarkers using Single...
This Project Grant award of $2,683,965.00 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program will fund the development and optimization of an "all-human cellular system" for studying Alzheimer's disease (AD) and age-related dementias (ADRDs). The primary objectives are to: 1) define delivery conditions for introducing patient blood cells and plasma into a...
The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded a $472,695 project grant to 3D Bioanalytix, Inc. to develop a blood-based diagnostic test for early detection and differentiation of neurodegenerative diseases such as Alzheimer's and Parkinson's. The project leverages the company's Covalent Protein Painting (CPP) platform technology to detect and identify misfolded protein aggregates that characterize these diseases. This novel...
This federal Project Grant award, valued at $441,612 and granted by the National Institute on Aging (CFDA 93.866 - Aging Research), supports research to investigate the relationship between modifiable risk factors and digital cognitive markers for early detection of cognitive decline associated with Alzheimer's disease. The project aims to leverage digital assessments, such as digital pen and voice recordings, in the Framingham Heart Study cohort to monitor cognitive changes in relation to...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $129,330 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop a multi-modal information framework that leverages decades-long in vivo and digital biomarkers to profile the inter-individual heterogeneity of Alzheimer's disease and related dementias (ADRD) and build a risk prediction model of time-to-diagnosis using machine learning and time series...
This $306,509 federal Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) to Captis Diagnostics Inc. aims to develop a technology platform for rapid magnetic isolation of neuronal extracellular vesicles (EVs) from blood plasma samples. The goal is to enable the detection of biomarkers for neurological diseases such as Alzheimer's, Parkinson's, and traumatic brain injury through a minimally invasive liquid biopsy approach. Key activities include developing...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop a new blood-based biomarker for the early detection and monitoring of Alzheimer's disease (AD). The $431,826 award, made on September 15, 2024, will fund the development of monoclonal antibodies to detect a newly discovered, neurotoxic amyloid-beta (Aβ) peptide dimer that is specific to AD pathology in the brain. The project involves the University of Wollongong conducting...
This National Institute on Aging (NIA) Project Grant award, provided under the Aging Research federal grant program (CFDA 93.866), supports a $197,569 study led by Dr. Emily Paolillo at the University of California, San Francisco (UCSF) to investigate the utility of passive smartphone monitoring to detect neurobehavioral impairment in neurodegenerative diseases like Alzheimer's and frontotemporal dementia. The overarching goal is to evaluate whether smartphone-based digital assessment tools...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $307,538 to Sage Cerebrovascular Diagnostics, Inc. to develop and validate a novel, minimally invasive diagnostic assay to discriminate Alzheimer's disease from vascular dementia. The award aims to: 1) establish the assay's performance characteristics in a clinical laboratory environment, 2) identify the optimal at-home sample collection methodology, and 3) determine the assay's sensitivity...
This $500,000 Project Grant was awarded on September 15, 2024 by the National Institute on Aging (CFDA 93.866 Aging Research program) to Neucyte Inc., a minority-owned small business specializing in advanced biomedical research and development. The funding will support the development of a miniaturized "mini-brain" microphysiological system (MPS) platform using Alzheimer's disease (AD) patient-derived cells. The goal is to create a scalable, reproducible in vitro brain model that can...